Slide Show: Highlights From the 2015 ASCO Breast Cancer Symposium

Slideshow
Conference|ASCO Breast Cancer Symposium

This slide show highlights some of the presentations that took place at the 2015 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in San Francisco, September 25-27, 2015.

References:

  • Caggiano V, Parise C. Racial/ethnic disparities in HER2-positive breast cancer in the era of adjuvant trastuzmab. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 139.
  • Hong JJ, Seksenyan A, Yuan X. et al. TOX3 as a novel biomarker in luminal B breast cancer. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 130.
  • Yadav S, Fulbright J, Dreyfuss H,  et al. Outcomes of retesting BRCA-negative patients using multigene panels. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 23.
  • Shafaee MN, Gutierrez-Barrera AM, Lin HL, Arun B. Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 3.
  • Hassan SN, Esch A, Heiser L, Gray JW. Biological indicators of response and resistance to PARP inhibition in BRCA wild-type breast cancer. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 125.
  • Chan A, Martin M, Von Minckwitz G. et al. Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 117.

 

 

 

 

 

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Enhances DCIS Risk Stratification Beyond Clincopathology

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer

Tim Cortese
July 29th 2025
Article

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

Ariana Pelosci
July 20th 2025
Article

Updated POSITIVE trial findings showed no significant breast cancer events in patients who breastfed following endocrine therapy for HR+ breast cancer.

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.